Bayer: Hyperphosphatemia trials

The registry lists 10 Hyperphosphatemia studies with Bayer as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2Phase 3 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fosrenol Post-marketing Surveillance in JapanCompletedNCT01955876
• Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis PatientsCompletedNCT01518387Phase 3
• Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium CarbonateCompletedNCT01514851Phase 3
• Fosrenol Post-marketing Surveillance for Hemodialysis in JapanCompletedNCT01419327
• Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in JapanCompletedNCT01412398
• Long-term Study in Chronic Kidney Disease (Extension From Study 14817)CompletedNCT01187628Phase 3
• Study in Chronic Kidney Disease (CKD) Not on DialysisCompletedNCT01110629Phase 3
• Bioequivalence Study of BAY77-1931 GranuleCompletedNCT01053676Phase 1
• BAY 77-1931 Long-term Extension From Phase II StudyCompletedNCT00769496Phase 2
• Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in BoneCompletedNCT00767637Phase 2